Adverum Biotechnologies (NASDAQ:ADVM) announces positive preliminary data from the first three cohorts in a Phase 1 dose-ranging clinical trial, OPTIC,
evaluating gene therapy candidate ADVM-022, administered via
intravitreal injection, in patients with wet age-related macular
degeneration (wet AMD).
The company says ADVM-022 continues to show
“robust” efficacy with long-durability of beyond a year from a single
administration with no rescue injections in cohort 1.
On the safety front, the gene therapy continues to be well-tolerated with a favorable safety profile.
Mean gain in best corrected visual acuity (BCVA) in cohort 3 was +6.8 letters.
It plans to file an IND for ADVM-022 in diabetic retinopathy (DR) this quarter.
Key H2 milestones: Present data from all four cohorts in OPTIC and launch enrollment in Phase 1/2 study of ADVM-022 in DR.
https://seekingalpha.com/news/3569040-adverum-gene-therapy-shows-positive-action-in-wet-amd-shares-up-22-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.